Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Plasminogen-activator-producing tumour.

Literature DB >> 5761832

Plasminogen-activator-producing tumour.

J F Davidson, G P McNicol, G L Frank, T J Anderson, A S Douglas.

Abstract

In a patient with giant-cell carcinoma of the lung a secondary tumour deposit in the arm was incised and bled for three weeks. Investigations showed the tumour to be rich in plasminogen activator. Haemostasis in the tumour was achieved with aminocaproic acid therapy. For a period the plasminogen-activator properties were retained in cell culture of the tumour.

Entities: Chemical Disease Species

Mesh：

Substances：

Year: 1969 PMID： 5761832 PMCID： PMC1982019 DOI： 10.1136/bmj.1.5636.88

Source DB: PubMed Journal: Br Med J ISSN： 0007-1447

13 in total

1. LOCALIZATION OF FIBRINOLYTIC ACTIVITY IN TISSUES.

Authors: A S TODD
Journal: Br Med Bull Date: 1964-09 Impact factor: 4.291

Review 2. A REVIEW OF UNUSUAL SYSTEMIC MANIFESTATIONS ASSOCIATED WITH CARCINOMA.

Authors: E GREENBERG; M B DIVERTIE; L B WOOLNER
Journal: Am J Med Date: 1964-01 Impact factor: 4.965

3. GIANT-CELL CARCINOMA OF THE LUNG: A DEDIFFERENTIATED ADENOCARCINOMA.

Authors: E C FRIEDBERG
Journal: Cancer Date: 1965-02 Impact factor: 6.860

4. PLASMA FIBRINOLYTIC ACTIVITY IN RENAL DISEASE.

Authors: G P MCNICOL; A A BARAKAT; A S DOUGLAS
Journal: Scott Med J Date: 1965-05 Impact factor: 0.729

5. Some properties of the cancer coagulative factor.

Authors: R A O'MEARA; R D THORNES
Journal: Ir J Med Sci Date: 1961-03 Impact factor: 1.568

6. Rotation-mediated histogenetic aggregation of dissociated cells. A quantifiable approach to cell interactions in vitro.

Authors: A MOSCONA
Journal: Exp Cell Res Date: 1961-01 Impact factor: 3.905

7. Activation of plasminogen.

Authors: S MULLERTZ
Journal: Ann N Y Acad Sci Date: 1957-08-30 Impact factor: 5.691

8. Prostatic fibrinolysin; study of a case illustrating role in hemorrhagic diathesis of cancer of the prostate.

Authors: H J TAGNON; P SCHULMAN; W F WHITMORE; L A LEONE
Journal: Am J Med Date: 1953-12 Impact factor: 4.965

9. Quantitative estimation of split products of fibrinogen in human serum, relation to diagnosis and treatment.

Authors: C Merskey; G J Kleiner; A J Johnson
Journal: Blood Date: 1966-07 Impact factor: 22.113

10. Origin of fibrinolytic activity in cultures of the human kidney.

Authors: M B Bernik; H C Kwaan
Journal: J Lab Clin Med Date: 1967-10

9 in total

1. Assessment of Urokinase-Type Plasminogen Activator and Its Inhibitor PAI-1 in Breast Cancer Tissue: Historical Aspects and Future Prospects.

Authors: Manfred Schmitt; Karin Mengele; Apostolos Gkazepis; Rudolf Napieralski; Viktor Magdolen; Ute Reuning; Nadia Harbeck
Journal: Breast Care (Basel) Date: 2008-10-15 Impact factor: 2.860

Review 5. Basis of antifibrinolytic therapy.

Authors: C R Prentice
Journal: J Clin Pathol Suppl (R Coll Pathol) Date: 1980

Plasminogen-activator-producing tumour.

1. LOCALIZATION OF FIBRINOLYTIC ACTIVITY IN TISSUES.

Review 2. A REVIEW OF UNUSUAL SYSTEMIC MANIFESTATIONS ASSOCIATED WITH CARCINOMA.

3. GIANT-CELL CARCINOMA OF THE LUNG: A DEDIFFERENTIATED ADENOCARCINOMA.

4. PLASMA FIBRINOLYTIC ACTIVITY IN RENAL DISEASE.

5. Some properties of the cancer coagulative factor.

6. Rotation-mediated histogenetic aggregation of dissociated cells. A quantifiable approach to cell interactions in vitro.

7. Activation of plasminogen.

8. Prostatic fibrinolysin; study of a case illustrating role in hemorrhagic diathesis of cancer of the prostate.

9. Quantitative estimation of split products of fibrinogen in human serum, relation to diagnosis and treatment.

10. Origin of fibrinolytic activity in cultures of the human kidney.

1. Assessment of Urokinase-Type Plasminogen Activator and Its Inhibitor PAI-1 in Breast Cancer Tissue: Historical Aspects and Future Prospects.

2. Identification of a plasminogen activator derived from nasopharyngeal carcinoma.

3. Secretion of hypothalamic and pituitary hormones by non-endocrine tumours.

4. Fibrin and cancer.

Review 5. Basis of antifibrinolytic therapy.

6. [Carcinofetal antigens. III. Further carcinofetal antigens (author's transl)].

7. Fibrin degradation products and ovarian tumours.

8. Aprotinin and growth of Walker 256 carcinosarcoma in the rat.

Review 9. Foetal antigens and their role in the diagnosis and clinical management of human neoplasms: a review.